The U.S. will let Novo Nordisk A/S sell it blockbuster weight loss drug Wegovy in a pill form. Millions of people already take the shot. A trial showed people taking a 25 milligram pill once daily lost about 13.6% of their body weight over 64 weeks. Novo President and CEO Mike Doustdar speaks to Bloomberg's Katie Greifeld.
Breakdown
- Novo Nordisk gains first-mover advantage with Wegovy pill in January. 5s
- Wegovy pill shows 17% efficacy; 1 in 3 users may lose up to 20% weight. 22s
- Pill matches injection efficacy, offering daily oral or weekly injectable options. 1m 31s
- Over 10 years of safety data and cardiovascular protection highlighted. 1m 47s
- Novo Nordisk prepared to compete as Eli Lilly enters market in March. 2m 3s